After acute illness or trauma there is a metabolic response which aims to reduce catabolism and conserve energy for essential organ systems. This is at least partly mediated by the endocrine system and results in several hormonal`abnormalitie s', for example, elevated serum cortisol and the`sickeuthyroid' syndrome. To date, the evidence shows that these mechanisms are essential for survival and do not require intervention. In prolonged critical illness, however, it is unclear whether these changes continue to be protective or have a deleterious e¡ect on recovery. For the latter circumstance, supplementation with hormone therapy may aid recovery.
Critically ill patients generally have increased cortisol concentrations, although the degree of elevation may be inadequate for the disease severity. It has been suggested that this may represent a state of relative' adrenal insu¤ciency. Several studies have used the short Synacthen test to identify such patients, with a response of 5250 nmol/ L suggesting relative adrenal insu¤ciency. Whilst there is no evidence to suggest bene¢ts for high-dose steroids in unselected ITU populations, there is increasing evidence that lowdose hydrocortisone improves morbidity in high-risk individuals.
In acute illness the pulsatility of GH secretion is lost, although the actual GH concentration may be low, normal or raised depending on the condition. In prolonged illness the serum IGF-1 concentration falls. Attempts to treat patients with GH resulted in increased mortality. This may have been caused by the high doses used in the study. The doses may have increased IGF concentrations to those normally seen in acromegaly, causing insulin resistance and £uid retention. The use of GH secretagogues to restore normal GH pulsatility is now the subject of further study.
Changes in TSH, T 3 and fT 3 are perhaps the most widely recognised hormonal changes during critical illness, and studies using thyroxine treatment have failed to show any bene¢t. As above, the use of TSH secretagogues may be shown to have more bene¢cial e¡ects.
The metabolic response to acute illness is essential for survival. In prolonged illness a pattern of hormone changes occurs which is associated with a number of features, including increased catabolism and poor immune function, resulting in considerable morbidity and mortality. The endocrine system is ¢nely balanced, and attempts to`normaliz e' the perturbations associated with critical illness have not been successful. The exception is the use of low dose corticosteroid treatment in patients shown to have relative adrenal insu¤ciency. Studies are now underway using TRH and/or GHRH, aiming to restore pulsatile secretion to a more normal pattern and improve outcome. Thyroid cancer is the most common endocrine malignancy, but because it is a rare cancer there have been no prospective trials examining treatment options. There are several large and well documented retrospective series which have provided good evidence for the importance of adequate surgery, use of postoperative ablative radioiodine therapy and long-term T 4 therapy. In patients with di¡erentiated (papillary and follicular) cancer it has been suggested that the complexity of decision-making requires management according to locally agreed protocols by a specialist team including a surgeon, an endocrinologist and an oncologist.
This retrospective study reviewed the case notes of 205 patients with di¡erentiated thyroid cancer; 134 patients (group A) were managed in a specialist multidisciplinary clinic setting and 71 patients (group B) were managed in other clinic settings.
The audit revealed de¢ciencies in management, with signi¢cant di¡erences between the two groups in some areas of treatment.
Thyroxine administration was not documented clearly in 14% of cases, and in approximately one-¢fth there was biochemical evidence of inadequate replacement. Occurrence of regular monitoring of thyroglobulin was similar between the groups but there was a signi¢cantly higher proportion of high thyroglobulin values recorded in patients in group B that were not acted upon. A higher percentage of patients in group B were not given ablative 131 I when indicated and did not receive adequate surgery compared with patients in group A.
The conclusions from this review were that although patient management was judged to be suboptimal by the specialist team, there was a higher prevalence of de¢ciencies outside the specialist clinical setting. The authors favour centralization of expertise and highlight the need for the availability and adoption of national guidelines and protocols for management of patients with di¡erentiated thyroid cancer. About 80% of patients who die of prostatic disease have evidence of bone involvement at autopsy. Most lesions are osteoblastic. Current clinical treatment of metastatic deposits makes use of orchidectomy or LHRH-analogues to reduce tumour growth. Berruti et al. review bone physiology and biochemistry and how these are disrupted in patients with prostate cancer and bone metastases. Histological examination of bone from patients with metastatic disease demonstrates an increase in osteoblastic activity and an increase in the production of mineralized new bone adjacent to tumour tissue. Bone reabsorption is also increased but at sites that are distant from the areas of new bone formation. There are two mechanisms by which osteoclastic activity may be increased. First, as a result of secondary hyperparathyroidism consequent upon increased osteoblastic activity, leading to calcium entrapment within bone (about 15% of cases) and second, due to the iatrogenic e¡ect of orchidectomy and androgen deprivation.
Ruth Lapworth
Berruti et al. discuss the rationale for the use of bisphosphonates in prostate cancer. Bisphosphonates inhibit osteoclastic function and are used in situations where the pathology is a consequence of too much osteoclastic activity, e.g. osteoporosis, Paget's disease, multiple myeloma and advanced breast cancer with bone deposits. Could bisphosphonates have a role in metastatic prostate cancer treatment? If the underlying pathophysiology is that the excess osteoblastic activity is secondary to increased osteoclastic activity then bisphosphonate should, indeed, have a role to play by blocking osteoclastic activity. Randomized studies, however, have so far been disappointing. These studies have used pain relief in response to bisphosphonates as their end-point and have failed to show any bene¢t of the drugs over placebo. Nevertheless, bone pain may be caused by mechanical derangement or by the release of pro-in£ammatory markers, i.e. bone pain as the sole index of worth is questionable. Berruti et al. advocate that future trials should use onset of adverse skeletal events, pathological fractures, the need for surgery and the need for radiotherapy as better end-points for analysis of the e¤cacy of bisphosphonates. Perhaps men with prostate cancer who are about to undergo orchidectomy should be routinely o¡ered bisphosphonates to prevent the inevitable bone loss that follows this procedure.
The Prostate Cancer Working Party of the Medical Research Council (UK) has recently established a placebo-controlled, double-blind, randomized trial in which a bisphosphonate (clodronate) is given to patients with prostate cancer and bone metastases. The aim of the study is to determine whether or not there is prolongation to the time of relapse. A second trial by the same group is looking at the e¡ect of giving clodronate to men with prostate cancer but without evidence of bone metastases. There are also trials underway elsewhere but, at present, published data are insu¤cient to judge the e¤cacy of bisphosphonates in prostate cancer treatment.
This is an interesting review that illustrates our current knowledge of bone physiology and biochemistry and how it is thought that these are disrupted by prostate cancer. If you work in a hospital laboratory you may have been accused of being remote from the management of patients who attend your hospital. Likewise, medical doctors are accused of being too interested in the mechanisms of disease and not interested enough in the patient (person) before them. On the other side of the coin, many patients feel that hospital establishments de¢ne them according to their disease and do not pay enough attention to the social aspects of that disease. The editors of the Lancet have acknowledged these di¡erent camps and have invited (a) 33 doctors and scientists to write about their areas of expertise, and (b) people with ¢rst-hand knowledge of a disease to write about how that disease has a¡ected them. Many of the disorders described have traditionally been thought of as having a biochemical basis: diabetes mellitus, Gaucher's disease, erythropoietic protoporphyria, sitosterolaemia, etc, and many of the other disorders are shown to have a biochemical basis: breast cancer, Alzheimer's disease, prematurity and more.
JD Johnston
This supplement to the ¢nal 2001 edition of the Lancet is a splendid collection of essays that will bring the enquiring mind up to date with recent advances in our understanding of disease processes and also keep us in touch with the human side of our science.
Queen Elizabeth Hospital London, UK Contributions to Journal Watch are invited from all readers and should be sent to Julian H Barth, Associate Editor (j.h.barth@leeds.ac.uk).
